Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones

• Main Authors: Allocca, M. (Author), Andreotti, G. (Author), Bosso, A. (Author), Cubellis, M.V (Author), Liguori, L. (Author), Lukas, J. (Author), Mele, B.H (Author), Monti, M.C (Author), Monticelli, M. (Author), Morretta, E. (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: acetylsalicylic acid; AGAL; drug repositioning; Fabry disease; lysosomal storage diseases; pharmacological chaperones
• Online Access: View Fulltext in Publisher

 Fabry disease is caused by a deficiency of lysosomal alpha galactosidase and has a very large genotypic and phenotypic spectrum. Some patients who carry hypomorphic mutations can benefit from oral therapy with a pharmacological chaperone. The drug requires a very precise regimen because it is a reversible inhibitor of alpha-galactosidase. We looked for molecules that can potentiate this pharmacological chaperone, among drugs that have already been approved for other diseases. We tested candidate molecules in fibroblasts derived from a patient carrying a large deletion in the gene GLA, which were stably transfected with a plasmid expressing hypomorphic mutants. In our cell model, three drugs were able to potentiate the action of the pharmacological chaperone. We focused our attention on one of them, acetylsalicylic acid. We expect that acetylsalicylic acid can be used in synergy with the Fabry disease pharmacological chaperone and prolong its stabilizing effect on alpha-galactosidase. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.